Harbour gets Chinese rights to HanAll's biologics

Korean biotech HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Harbour BioMed (Shanghai, China) rights to develop and commercialize HL161 and HL036 for multiple indications in China,

Read the full 255 word article

How to gain access

Continue reading with a
two-week free trial.